The objective of this review is to report the Clinical Year in Review proceedings in the field of thoracic oncology that were presented at the 2013 European Respiratory Society Annual Congress in Barcelona, Spain. Various topics were reviewed, including: epidemiology, screening, histology, and treatment of nonsmall cell lung cancer and small cell lung cancer.

Lung cancer is the leading cause of cancer-related death in United States and incidence this never smokers about 15-20% males 50% females. Non-small cell lung carcinoma (NSCLC) constitutes 75% to 80% these cancers more common than small (SCLC) smokers. Treatment NSCLC has been rapidly evolving with discovery targetable mutations like EGFR, ALK. Despite this, prognosis remains guarded given diag...

Treating patients with advanced nonsmall cell lung cancer (NSCLC) is a daunting task but during recent years new options have emerged. By tailoring treatment using either information on histological subtypes of NSCLC or biomarkers it is now possible to improve outcome and maintain stable quality of life. We conducted a literature search of tailored treatment already implemented in advanced NSCL...

BACKGROUND We investigated factors predicting postoperative recurrence in patients with pathological Stage I nonsmall cell lung cancer (NSCLC). METHODS All patients with clinical Stage I NSCLC who underwent surgical resection at Tri-Service General Hospital in Taiwan between January 2002 and June 2006 were reviewed retrospectively. All study patients underwent standard staging workups. We rev...

Immuno-oncology marked a therapeutic revolution in the treatment of cancer. Thanks to new strategy that aims awaken immune system fight cancer cells, there has been change clinical course advanced Non- Small Cell Lung Cancer (NSCLC). Our study aimed evaluate efficacy nivolumab monotherapy patients with stage IIIB/IV non-small cell lung beyond second line. The results showed progression-free sur...

Severe haemoptysis due to nonsmall cell lung cancer (NSCLC) is considered a grim condition, and there is still scarce data on its characteristics and outcome, despite new imaging and treatment modalities. This retrospective study sought to describe the clinical characteristics, pathophysiology and outcome of NSCLC-related haemoptysis. We included 125 consecutive patients with severe haemoptysis...

Targeted therapy (TT) has revolutionized cancer treatment, successfully applied in various settings. Adjuvant TT resected early-stage gastrointestinal stromal tumors (GIST), melanoma, non-small cell lung (NSCLC), and breast led to practice-changing achievements. In particular, standard treatments include BRAF inhibitors for osimertinib NSCLC, hormone or HER2 cancer, imatinib GIST. Despite the u...

 Abstract 9025 Genomic profiling of circulating tumor DNA (ctDNA) from patients (pts) with advanced non-small cell lung cancer (NSCLC). Poster Board #351  Abstract 9064 Updated efficacy and safety of the j-alex study comparing alectinib (ALC) with crizotinib (CRZ) in ALK-inhibitor naïve ALK fusion positive non-small cell lung cancer (ALK+ NSCLC). Poster Board #390  Abstract 9092 Atezolizumab...

Companion diagnostics are an emerging and exciting field in the care of oncology patients. These tests accompany standard diagnostic investigations in cancer patients and function as an aid in treatment decision making. A great number of new compounds are under clinical and laboratory testing in nonsmall cell lung cancer (NSCLC). As the variety of therapeutic options expands in the various sett...

Even when patients with nonsmall cell lung cancer undergo surgical resection at an early stage, recurrent disease often impairs the clinical outcome. There are numerous causes potentially responsible for a relapse of the disease, one of them being extensive angiogenesis. The balance of at least two systems, VEGF VEGFR and Ang Tie, regulates vessel formation. The aim of this study was to determi...